Clinical Trials on Impaired Glucose Tolerance in Canada

Total 1407 results

AstraZeneca

Completed

Extension Study for 2993-112

Type 2 Diabetes Mellitus

United States, Canada
Eli Lilly and Company
Alkermes, Inc.

Completed

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Puerto Rico, United States, Spain, India, Belgium, Argentina, Austria, France, Mexico
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)

Diabetes | Type 2 Diabetes

United States, China, Germany, Mexico, Brazil, Canada, Japan, Korea, Republic of, Puerto Rico, Czechia, Greece
Merck Sharp & Dohme LLC
Pfizer

Active, not recruiting

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Type 2 Diabetes Mellitus

United States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russian Federation, Saudi Arabia, Turkey, Ukraine, United Arab... and more
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Novo Nordisk A/S

Completed

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Israel, Italy, Mexico, Puerto Rico, Russian Federation, Spain, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Taiwan, Finland, Norway, Serbia, South Africa, Turkey, Canada, France, Germany, Korea, Republic of and more
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes (ADJUNCT TWO™)

Diabetes | Diabetes Mellitus, Type 1

United States, Italy, Canada, Denmark, Finland, Spain, Netherlands, Austria, Sweden, Belgium, France, Bulgaria, South Africa
Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (LixiLan-G)

Type 2 Diabetes Mellitus

Estonia, Italy, Israel, United States, Canada, Germany, Romania, Slovakia, Spain
Boehringer Ingelheim
Eli Lilly and Company

Completed

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Diabetes Mellitus, Type 2

United States, Spain, Taiwan, United Kingdom, Czechia, Bulgaria, Israel, Canada, Germany, Malaysia, Argentina, Hungary, Russian Federation, Poland, Ukraine, Korea, Republic of, Croatia, Japan, Netherlands, Portugal, South Africa, ... and more
National Institute of Diabetes and Digestive and...
Juvenile Diabetes Research Foundation

Terminated

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus (TN-22)

Type1 Diabetes Mellitus

United States, Australia, Italy, United Kingdom, Sweden, Canada
Gilead Sciences

Completed

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Type 2 Diabetes Mellitus

United States, Russian Federation, Israel, South Africa, India, Hungary, Ukraine, Canada, Czech Republic, Mexico, Poland
Sanofi

Completed

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs (LIXILAN JP-L)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-L)

Type 2 Diabetes

United States, Australia, Canada, Chile, Czech Republic, Denmark, Estonia, Hungary, Lithuania, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine
Abbott

Completed

Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus (TARDIA)

Hypertension

Bulgaria, Czech Republic, Romania, Russian Federation, Slovakia, Slovenia, Ukraine
AstraZeneca

Completed

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Austria, Canada, Italy, Netherlands, Spain, United Kingdom, Taiwan, Thailand, Bulgaria, Belgium, Germany, Korea, Republic of, Hungary, Philippines, China, Malaysia, Hong Kong, New Zealand, Argentina, Czechia, Slovakia, Braz... and more
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes (onset®8)

Diabetes | Diabetes Mellitus, Type 1

United States, India, Israel, Italy, Japan, Russian Federation, Canada, Austria, Taiwan, Serbia, Germany, Bulgaria, Puerto Rico
Mannkind Corporation

Completed

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Brazil, Spain, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, Ukraine, Czech Republic
Eli Lilly and Company

Recruiting

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3)

Type 2 Diabetes

United States, China, Japan, Argentina, Puerto Rico, Mexico
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (SOTA-GLIM)

Type 2 Diabetes Mellitus

United States, Bulgaria, Hungary, Slovakia
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (onset® 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN™ 4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, United Kingdom, France, Argentina, South Africa, Germany, Slovenia, Netherlands, Romania, North Macedonia, Mexico, Puerto Rico
Eli Lilly and Company

Completed

A Study in Patients With Type 2 Diabetes Mellitus (IMAGINE 2)

Diabetes Mellitus, Type 2

United States, Brazil, Germany, Israel, Italy, United Kingdom, Australia, Hungary, Puerto Rico, Romania, Russian Federation, Spain, Poland, Canada, Greece, Turkey, Mexico, New Zealand, South Africa, Argentina, Finland, Lithuania, Sl...
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
Novo Nordisk A/S

Terminated

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus (EDITION JUNIOR)

Type 1 Diabetes Mellitus

France, Czechia, Chile, Israel, Spain, Hungary, Mexico, Serbia, Japan, Canada, Brazil, Sweden, Denmark, Argentina, United States, Bulgaria, Germany, Italy, Latvia, North Macedonia, Poland, Romania, Russian Federation, United Kingdom
GlaxoSmithKline

Completed

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD)

Diabetes Mellitus, Type 2

Spain, Finland, Bulgaria, Belgium, Sweden, Denmark, Germany, Australia, Hungary, Italy, New Zealand, Russian Federation, Ukraine, Estonia, Slovakia, France, Greece, Poland, United Kingdom, Czech Republic, Netherlands, Croatia, Lithu... and more
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico
AstraZeneca

Completed

Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey (PANORAMA)

Diabetes

France, Spain, United Kingdom, Germany, Greece, Italy, Netherlands, Ireland
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (ADJUNCT ONE™)

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Poland, United Kingdom, France, Sweden, Netherlands, Finland, Belgium, Ireland, Germany, Canada, Russian Federation, Australia, Norway, Argentina, Ukraine
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Diabetes Mellitus Type 2

Sweden, United States, Mexico, South Africa, Russian Federation, France, Spain, Switzerland, Canada, Finland, New Zealand, Korea, Republic of, Thailand, Israel, Germany, Peru, Australia, Denmark, Italy, Ukraine, Greece, Puerto Rico, Guatemal... and more
Eli Lilly and Company
Alkermes, Inc.

Completed

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Belgium, Canada, Croatia, Hungary, India
Eli Lilly and Company
Alkermes, Inc.

Completed

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany, Puerto Rico, United Kingdom, Spain, Canada, Brazil, Korea, Republic of, India, Israel, Russian Federation, South Africa
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem2)

Type 1 Diabetes Mellitus

Israel, Italy, Spain, Bulgaria, Hungary, Poland, Slovakia, United Kingdom, Austria, Belgium, France, Germany, Lithuania, Netherlands, Romania, Sweden, Switzerland
Bristol-Myers Squibb

Completed

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

South Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
AstraZeneca

Completed

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Canada, Czechia, Germany, Russian Federation, Mexico
Novo Nordisk A/S

Active, not recruiting

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS)

Diabetes Mellitus, Type 2

Spain, United States, India, Czechia, Canada, Latvia, United Kingdom, Portugal, Serbia, Poland, Romania, Brazil, Russian Federation, Slovakia, Bulgaria, Mexico, Germany, Greece, Israel
Biogen

Terminated

Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy

Diabetes Mellitus | Small Fiber Neuropathy

Bulgaria, Poland, Spain, United Kingdom, Canada, France, Czechia, Germany, Hungary, Greece, Denmark, Italy, Netherlands, Switzerland
Chelsea Therapeutics

Completed

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (NOH303)

Multiple System Atrophy | Neurogenic Orthostatic Hypotension | Dopamine Beta Hydroxylase Deficiency | Non-Diabetic Autonomic Neuropathy

United States, Australia, Canada, New Zealand
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O)

Type 2 Diabetes Mellitus

Estonia, Spain, Ukraine, Italy, Germany, Canada, Mexico, United States, Argentina, Bulgaria, Chile, Denmark, Finland, Hungary, India, Korea, Republic of, Latvia, Lithuania, Norway, Peru, Poland, Romania, Russian Federation, Serbia, Slov... and more
AstraZeneca

Completed

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings (DISCOVER)

Type 2 Diabetes Mellitus

Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, South Africa, Spain, Turkey, China, Netherlands, Argentina, Austria, Czechia, United Arab Emirates, Taiwan, India, Egypt, Saudi Arabia, Lebanon, Indonesia, Col... and more
Novo Nordisk A/S

Completed

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin (SCALE™ Insulin)

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Italy, Mexico, Canada, Germany, Turkey
GlaxoSmithKline

Completed

Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension

Hypertension

United States
Takeda

Completed

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus (PERISCOPE)

Diabetes Mellitus

United States, Argentina, Canada, Chile
AstraZeneca

Terminated

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Brazil, Czech Republic, Italy, Korea, Republic of, Russian Federation, South Africa, United Kingdom, Vietnam, Philippines, Malaysia, Estonia, Latvia, Lithuania, Poland, Finland, Canada, Hong Kong, Argentina, Hun... and more
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
Pfizer

Terminated

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Canada, Brazil, Mexico, Argentina
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Type 2 Diabetes Mellitus

Russian Federation, United States, Puerto Rico, Australia, Taiwan, Israel, Spain, Canada, Greece, Argentina, Poland, Romania, Mexico, Slovakia, Brazil

Clinical Trials on Impaired Glucose Tolerance in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations